Revenue up 46%; consolidated net profit up 249%; stamp duty case flagged
AARTIPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 5.8 pts more than Nifty Microcap 250 and 6.1 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Board approved September-quarter standalone revenue of Rs 61,259 lakh, up 46% year on year, and net profit of Rs 6,575 lakh, up 180%. Consolidated net profit rose 249% to Rs 7,147 lakh; half-year revenue rose 42% and profit 122%. Auditors highlighted a Rs 204 lakh provision, Rs 5,746 lakh contingent liability in a pending stamp duty case, and restated 2025 figures. Chief Financial Officer Piyush Lakhani leaves October 30; Vibha Thakkar starts October 31.
Strong growth supports sentiment, but the Rs 5,746 lakh contingent liability, lower operating cash flow and finance chief change may cap gains.